Hospital Duran i Reynals L'Hospitalet

L'Hospitalet de Llobregat, Barcelona 08908

0 studies enrolling now · 1 studies all time

What they study most

Non-Hodgkin's Lymphoma

Studies at this site

• A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma — Running, not enrolling